Table 1 Clinical characteristics and data of AIDS patient with CM in the study cohort
Variables | Total(n = 128) | Effective cohort(n = 101) | Ineffective cohort(n = 27) | Statistic | P-value |
|---|---|---|---|---|---|
age | 37.5 (30.25, 46.75) | 36 (30, 44.5) | 42.3 ± 13.5 | −1.981 | 0.048 |
Sex (cases) | |||||
 Male | 113 (88.3%) | 92 (91.1%) | 21 (77.8%) | −1.903 | 0.057 |
 Female | 15 (11.7) | 9 (8.9%) | 6 (22.2%) | ||
Complications (cases) | |||||
 Tuberculous meningitis | 14 (10.9%) | 9 (8.9) | 5 (18.5%) | −1.415 | 0.157 |
 Purulent meningitis | 9 (7%) | 6 (5.9%) | 3 (11.1%) | −0.930 | 0.352 |
 Cryptococcal pneumonia | 31 (24.2%) | 26 (25.7%) | 5 (18.5%) | −0.775 | 0.438 |
 Epilepsy | 11 (8.6%) | 10 (9.9%) | 1 (3.7%) | −1.017 | 0.309 |
 Optic papillary edema | 6 (4.7%) | 5 (5%) | 1 (3.7%) | −0.271 | 0.786 |
 Deafness | 6 (4.7) | 6 (5.9%) | 0 (0%) | −1.292 | 0.196 |
 Hydrocephalus | 3 (2.3%) | 2 (2%) | 1 (3.7%) | −0.524 | 0.600 |
 Cerebral hernia | 4 (3.1%) | 2 (2%) | 2 (7.4%) | −1.434 | 0.152 |
 Cerebral infarction | 8 (6.3%) | 4 (4%) | 4 (14.8%) | −2.062 | 0.039 |
Signs and symptoms (cases) | |||||
 Fever | 109 (85.2%) | 89 (88.1%) | 20 (74.1%) | −1.816 | 0.069 |
 Sweat | 29 (22.7%) | 24 (23.8%) | 5 (18.5%) | −0.576 | 0.565 |
 Headache | 119 (93%) | 93 (92.1%) | 26 (96.3%) | −0.758 | 0.448 |
 Nausea and vomiting | 95 (74.2%) | 76 (75.2%) | 19 (70.4%) | −0.513 | 0.608 |
 Consciousness disorder | 52 (40.6%) | 36 (35.6%) | 16 (59.3%) | −2.211 | 0.027 |
 Eye disease | 41 (32%) | 31 (30.7%) | 10 (37%) | −0.625 | 0.532 |
 Cranial nerve injury | 38 (29.7%) | 27 (26.7%) | 11 (40.7%) | −1.410 | 0.159 |
 Neck resistance | 82 (64.1%) | 65 (64.4%) | 17 (63%) | −0.134 | 0.894 |
 Pathological signs | 25 (19.5%) | 19 (18.8) | 6 (22.2%) | −0.396 | 0.692 |
CSF pressure (mmH2O) | |||||
  < 180 | 25 (19.5%) | 23 (22.8%) | 2 (7.4%) | −1.741 | 0.082 |
 180–250 | 38 (29.7%) | 30 (29.7%) | 8 (29.6%) | ||
  > 250 | 65 (50.8%) | 48 (47.5%) | 17 (63%) | ||
CSF routine and biochemical | |||||
 WBC (cells/μl) | 20 (10, 59) | 20 (10, 61.5) | 23 (10, 50) | −0.138 | 0.891 |
 TP(g/L) | 40.4 (30.8, 73.85) | 38.6 (30.5, 64.9) | 50.3 (30.9, 91) | −1.256 | 0.209 |
 GLU (mmol/L) | 2.45 ± 0.95 | 2.51 ± 0.89 | 2.24 ± 1.15 | 1.110 | 0.275 |
 CL (mmol/L) | 117.9 ± 6.38 | 118.47 ± 5.78 | 115.76 ± 8.02 | 1.647 | 0.109 |
Etiological examination positive (cases) | |||||
 CSF Ink stain | 105 (82%) | 84 (83.2%) | 21 (77.8%) | −0.646 | 0.519 |
 CSF Cryptococcus antigen | 128 (100%) | 101 (100%) | 27 (100%) | 0.000 | 1.000 |
 CSF Cryptococcus culture | 75 (58.6%) | 59 (58.4%) | 16 (59.3%) | −0.079 | 0.937 |
 Blood Cryptococcus antigen | 125 (97.7%) | 99 (98%) | 26 (96.3%) | −0.524 | 0.600 |
 Blood Cryptococcus culture | 67 (52.3%) | 54 (53.5%) | 13 (48.1%) | −0.489 | 0.625 |
WBC(×109/L) | 4.97 (3.37, 6.59) | 4.94 (3.19, 6.82) | 5.57 ± 2.04 | −0.873 | 0.383 |
NE%(%) | 78.26 (66.64, 83.26) | 78.11 (65.8, 82.58) | 76.63 ± 13.56 | −1.171 | 0.242 |
LY%(%) | 12.97 (7.92, 20.15) | 12.92 (7.97, 20.85) | 14.89 ± 11.1 | −0.447 | 0.655 |
HGB(g/L) | 120.04 ± 22.59 | 118.76 ± 22.47 | 124.80 ± 22.84 | −1.237 | 0.218 |
PLT(×109/L) | 175.5 (128.5, 226.25) | 176 (117.5, 225.5) | 166.50 ± 68.80 | −0.517 | 0.605 |
ESR (mm/h) | 41 (21.5, 66) | 46.17 ± 27.77 | 27 (13, 68) | −1.481 | 0.139 |
CRP (mg/L) | 13.05 (4.58, 38.88) | 14.7 (5.46, 47.6) | 7.5 (3.6, 31) | −1.273 | 0.203 |
PCT (ng/ml) | 0.05 (0.05, 0.19) | 0.06 (0.05, 0.21) | 0.05 (0.05, 0.16) | −0.489 | 0.625 |
K (mmol/L) | 3.58 ± 0.53 | 3.62 ± 0.53 | 3.43 ± 0.55 | 1.613 | 0.109 |
Na (mmol/L) | 131.98 ± 5.51 | 132.09 ± 5.28 | 131.59 ± 6.38 | 0.417 | 0.677 |
Cl (mmol/L) | 97.23 ± 5.54 | 97.42 ± 5.26 | 96.51 ± 6.54 | 0.756 | 0.451 |
GLU (mmol/L) | 6.33 (5.67, 7.46) | 6.11 (5.54, 7.04) | 6.91 (6.23, 8.1) | −2.695 | 0.007 |
CD4(cells/μl) | 22.5 (9.25, 47) | 21 (9, 46) | 26 (10, 55) | −0.973 | 0.331 |
HIV RNA (copies/ml) | 68,466.5 (18,675.5, 186,018.5) | 84,218 (14,286, 182,126) | 31,659 (19,412, 190,202) | −1.072 | 0.284 |
Start/Unstart ART (cases) | 32/96 | 25/76 | 7/20 | 0.016 | 0.901 |
Treatment timing/Course (weeks) | 4 (3, 8) | 4 (2, 8) | 4 (3, 9) | −0.672 | 0.502 |
Therapeutic schedule (cases) | |||||
 AmB ± 5FC | 8 (6.3%) | 7 (6.9%) | 1 (3.7%) | −1.825 | 0.068 |
 FLU±5FC | 57 (44.5%) | 47 (46.5%) | 10 (37%) | ||
 Voriconazole | 4 (3.1%) | 4 (4.0%) | 0 (0%) | ||
 Mixed regimens | 39 (30.5%) | 31 (30.7%) | 8 (29.6%) | ||
 Non-standard treatment | 20 (15.6%) | 12 (11.9%) | 8 (29.6%) | ||
Induction course (weeks) | 5 (3, 10) | 7 (4, 10) | 2 (1, 5) | −4.398 | < 0.001 |